Largely driven by increasing incidence of chronic and infectious diseases and growth in biotechnology and pharma industries, the global immunoassay market is projected to reach USD 49.5 billion by 2027 from USD 40.23 billion in 2022, at a CAGR of 4.3%.From a global perspective, immunoassays are regarded as the frontline diagnostics for early-stagediagnosis and conducting epidemiological studies.

With a wide range of applications, immunology continues to play an important role in improving patient outcomes by enabling research and development of therapeutics. 

Increasing use of immunoassays in oncology

The growing incidence of various types of cancers has led to the development of innovative and advanced immunoassay techniques to effectively screen oncology biomarkers in samples. In recent years, immune-oncology therapeutics, used to stimulate the patient's immune system to achieve a long-term response against cancer, are currently included in treatment protocols. In fact, in India, there have been several recent advances in cancer immunotherapy research and treatment.

Growth in the biotechnology and biopharmaceutical markets

Immunoassays play a crucial role in drug discovery and monitoring with ELISA and radioimmunoassay being used for immunogenicity assessment of various biologics.Globally, in 2022, immunology drugs represented a significant portion of the new drug market and are forecasted as a key area of growth for specialty pharmacies in the next few years.Several studies point to thegrowingapplication of genomic immunohistochemistry in targeted therapy to develop improved recombinant monoclonal antibodies.

A surge in autoimmune diseases

Autoimmune diseases afflict nearly 5% of the global population and epidemiological studies have shown a steady rise in their incidence and prevalencein the last decade. It is interesting to note that, recent studies have indicated that environmental factors such as pollution account for 40-70% of all autoimmune diseases3. Traditional immunology techniques such as ELISA, IFA, Immunoblot and CLIA areroutinelydeployed for the detection of various clinical implications like allergies and autoimmune diseases. Design improvements in immunoassays and a deeper understanding of genetics are playing a major role in studying specific antibody structures, signal generation and detection of a greater number of autoimmune diseases. As a result of the improvements, the detection assays are more specific and accurate for disease diagnosis thus offering enhanced patient care. 

Thermo Fisher Scientific offers Gold Standard methods for allergy and autoimmunity testing

At Thermo Fisher Scientific, we are inspired by our Mission, to enable our customers to make the world healthier, cleaner and safer. As a global leader in allergy and autoimmune diagnostics, we provideaccurate and clinically relevant testing solutions to aid disease diagnosis and patient management.

The EliA™ autoimmunity solutions comprise an evolving portfolio of more than 50 clinically relevant, highly sensitive and specific tests, for autoimmune diseases. The assays can aid in fast and accurate diagnoses by detecting relevant antibodies. In some cases, these antibodies are present in the early disease stage and even when there are no clinical symptoms presented.

As the gold standard in in-vitro allergy diagnostics, ImmunoCAP tests help laboratories with results to optimize diagnosis and develop evidence-based symptom-management plans.

The fully automated and scalable Phadia™ Laboratory Systems, which run both ImmunoCAP and EliA tests, are designed to optimize workflow efficiency for any sized laboratory, enabling labs to increase productivity with limited resources. 

Further, our support teams providecustomers with clinical and laboratory training and support, including enhanced clinical insights beyond results.